产品
编 号：F749370
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
结构图
CAS No: 2147698-66-4
产品详情
生物活性：
Ifabotuzumab (KB004) is an IgG1κ antibody targeting EphA3 (KD=610 pM). Ifabotuzumab induces tumor cell apoptosis, activates Antibody-dependent cell mediated cytotoxicity (ADCC), and damages tumor vasculature. Ifabotuzumab reduces human idiopathic pulmonary fibrosis (IPF) CCR10+ cells and improves pulmonary fibrosis.
体内研究：
Ifabotuzumab (5 mg/kg; 腹腔注射; 每周 2 次, 共 5 周) 在肺纤维化人源小鼠模型中具有改善作用。Animal Model:Humanized NSG mice with lung fibrosis
Dosage:5 mg/kg
Administration:Intraperitoneal injection; twice weekly for 5 weeks
Result:Significantly reduced hydroxyproline to levels and IL-6 transcript levels.Significantly reduced the total number of CCR10+EphA3+, as well as Lin-CCR10+ cells.
Ifabotuzumab (KB004) is an IgG1κ antibody targeting EphA3 (KD=610 pM). Ifabotuzumab induces tumor cell apoptosis, activates Antibody-dependent cell mediated cytotoxicity (ADCC), and damages tumor vasculature. Ifabotuzumab reduces human idiopathic pulmonary fibrosis (IPF) CCR10+ cells and improves pulmonary fibrosis.
体内研究：
Ifabotuzumab (5 mg/kg; 腹腔注射; 每周 2 次, 共 5 周) 在肺纤维化人源小鼠模型中具有改善作用。Animal Model:Humanized NSG mice with lung fibrosis
Dosage:5 mg/kg
Administration:Intraperitoneal injection; twice weekly for 5 weeks
Result:Significantly reduced hydroxyproline to levels and IL-6 transcript levels.Significantly reduced the total number of CCR10+EphA3+, as well as Lin-CCR10+ cells.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备